SLC5A2 and type 2 diabetes mellitus: Because long-term drug expenditure dominates direct medical costs in T2DM, selection of metformin whenever clinically appropriate remains the fiscally prudent strategy, reserving SGLT2 inhibitors for patients with established cardiorenal indications where their incremental benefit is proven.